Morisot P, Loygue J, Guilmet C
Can Anaesth Soc J. 1975 Mar;22(2):144-8. doi: 10.1007/BF03004969.
A prospective study was undertaken to assess the influence of neostigmine, a reversal agent for curarimimetic myorelaxants, on the incidence of postoperative disruption of anastomotic sites. Over a period of one year, 400 patients had surgery, including anastomosis, on the digestive tract for a variety of surgical conditions (Table II). At the end of anaesthesia, 200 patients received doses of atropine and neostigmine, usually 1 mg and 2.5 mg of each, as indicated on clinical basis and neuromuscular stimulation. The other patients did not recieve these drugs and were ventilated till the myorelaxation vanished spontaneously. During the postoperative period of incidence of anastomotic breakdown was assessed by the surgeon, unaware of the use or the omission of neostigmine in his patients. Anastomotic leakage was classified in four groups, namely: proved, absent, likely and unlikely. In this series and according to these clinical criteria, both groups had an incidence of anastomotic breakdown which was not significantly different (Table III). Neostigmine as used in this work does not seem to compromise the normal healing of anastomotic sites on the digestive tract.
开展了一项前瞻性研究，以评估用于拮抗类箭毒样肌松剂的逆转剂新斯的明对术后吻合口破裂发生率的影响。在一年的时间里，400例患者因各种外科病症接受了包括消化道吻合术在内的手术（表二）。麻醉结束时，200例患者根据临床情况和神经肌肉刺激情况接受了阿托品和新斯的明剂量，通常各为1毫克和2.5毫克。其他患者未接受这些药物，持续通气直至肌松作用自行消失。在术后期间，由对其患者是否使用新斯的明不知情的外科医生评估吻合口破裂的发生率。吻合口漏分为四组，即：确诊、无、可能和不太可能。在本系列研究中，根据这些临床标准，两组吻合口破裂的发生率无显著差异（表三）。本研究中使用的新斯的明似乎不会影响消化道吻合口的正常愈合。
